Blood Test Detects Chronic Traumatic Encephalopathy During Life
|
By LabMedica International staff writers Posted on 22 Mar 2016 |
|
Image: The NanoSight LM10 instrument provides an easy-to-use, reproducible platform for nanoparticle characterization (Photo courtesy of Malvern Instruments).
Chronic traumatic encephalopathy (CTE) is a tauopathy associated with prior exposure to repetitive head impacts, such as those incurred through American football and other collision sports and diagnosis is made through neuropathological examination.
A method has been developed for measuring plasma exosomal tau. Exosomes are very small vesicles that are released from all types of cells throughout the body, including brain cells. They can be isolated in all body fluids, including plasma, a component of blood.
Scientists at Boston University School of Medicine (MA, USA) and their colleagues examined 78 former National Football League (NFL) players and a control group of 17 former non-contact sport athletes. Extracellular vesicles were isolated from plasma. Fluorescent nanoparticle tracking analysis was used to determine the number of vesicles staining positive for tau. Blood was drawn by venipuncture and immediately processed. Plasma samples were stored in 0.75 mL tubes at -80 °C, packed in dry ice, and shipped overnight in one batch to the Exosome Sciences laboratory (Monmouth Junction, NJ, USA).
Extracellular vesicles were isolated from the plasma samples by size exclusion chromatography. Plasma samples were applied to the column and it was then run isocratically. The elution was monitored at 280 nm and the void volume material (exosome fraction) was collected and pooled. The size profiles and concentrations of the chromatographically isolated exosomes were performed using the Nanosight LM10 instrument (Malvern Instruments Ltd.; Malvern, UK) equipped with a 405 nm laser, a scientific complementary metal-oxide-semiconductor (sCMOS) camera and Nanoparticle Tracking Analysis (NTA) software.
The method of measuring plasma exosomal tau is referred to as a TauSome. The groups did not differ in total plasma exosomes, but the NFL group had significantly higher plasma exosomal tau than the control group. The C-statistic is maximized when the plasma exosomal tau level is set to 0. Using 0 as a threshold resulted in 82% sensitivity, 100% specificity, 100% positive predictive value and 53% negative predictive value. The number of tau-positive plasma exosomes was significantly correlated with performance on standardized tests of memory and psychomotor speed; the higher the TauSome level, the worse the performance.
Jim Joyce, Founder of Exosome Sciences and Chairman and CEO of Aethlon Medical (San Diego, CA, USA), said, “We are extremely pleased that our initial study data has been published and we appreciate forthcoming opportunities to further advance our TauSome biomarker as a noninvasive solution to detect and monitor CTE in living individuals.” The study was published on February 10, 2016, in the Journal of Alzheimer's Disease.
Related Links:
Boston University School of Medicine
Exosome Sciences
Malvern Instruments Ltd.
A method has been developed for measuring plasma exosomal tau. Exosomes are very small vesicles that are released from all types of cells throughout the body, including brain cells. They can be isolated in all body fluids, including plasma, a component of blood.
Scientists at Boston University School of Medicine (MA, USA) and their colleagues examined 78 former National Football League (NFL) players and a control group of 17 former non-contact sport athletes. Extracellular vesicles were isolated from plasma. Fluorescent nanoparticle tracking analysis was used to determine the number of vesicles staining positive for tau. Blood was drawn by venipuncture and immediately processed. Plasma samples were stored in 0.75 mL tubes at -80 °C, packed in dry ice, and shipped overnight in one batch to the Exosome Sciences laboratory (Monmouth Junction, NJ, USA).
Extracellular vesicles were isolated from the plasma samples by size exclusion chromatography. Plasma samples were applied to the column and it was then run isocratically. The elution was monitored at 280 nm and the void volume material (exosome fraction) was collected and pooled. The size profiles and concentrations of the chromatographically isolated exosomes were performed using the Nanosight LM10 instrument (Malvern Instruments Ltd.; Malvern, UK) equipped with a 405 nm laser, a scientific complementary metal-oxide-semiconductor (sCMOS) camera and Nanoparticle Tracking Analysis (NTA) software.
The method of measuring plasma exosomal tau is referred to as a TauSome. The groups did not differ in total plasma exosomes, but the NFL group had significantly higher plasma exosomal tau than the control group. The C-statistic is maximized when the plasma exosomal tau level is set to 0. Using 0 as a threshold resulted in 82% sensitivity, 100% specificity, 100% positive predictive value and 53% negative predictive value. The number of tau-positive plasma exosomes was significantly correlated with performance on standardized tests of memory and psychomotor speed; the higher the TauSome level, the worse the performance.
Jim Joyce, Founder of Exosome Sciences and Chairman and CEO of Aethlon Medical (San Diego, CA, USA), said, “We are extremely pleased that our initial study data has been published and we appreciate forthcoming opportunities to further advance our TauSome biomarker as a noninvasive solution to detect and monitor CTE in living individuals.” The study was published on February 10, 2016, in the Journal of Alzheimer's Disease.
Related Links:
Boston University School of Medicine
Exosome Sciences
Malvern Instruments Ltd.
Gold Member
Aspiration System
VACUSAFE
Automated Urinalysis Solution
UN-9000
New
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
Latest Clinical Chem. News
- Blood Protein Panel Predicts Timing of ALS Symptom Onset
- Siemens Adds CE-Marked Capillary Claims for 24 Assays on Atellica Analyzers
- Preoperative Blood Test Predicts Colorectal Cancer Recurrence and Metastasis
- New Machine-Learning Equation Improves LDL Cholesterol Assessment
- Ultrasensitive Biosensor Detects Early Liver Fibrosis from Blood
- Blood Biomarker May Signal Cognitive Decline Risk a Decade Before Symptoms
- Blood Test Improves Alzheimer’s Diagnosis Across Care Settings
- New Immunoassay Enables Ultrasensitive Blood-Based Tau Tangle Measurement
- Blood Hormone Pattern Distinguishes Endometriosis with High Accuracy
- Blood Test Brings Alzheimer’s Biomarker Assessment to Routine Labs
- Alzheimer’s Biomarkers Identify Faster Cognitive Decline in Adults Over 80
- ADLM Issues Laboratory Guidance for Gender-Diverse Patient Care
- FDA-Approved Test Identifies Low Risk of Large Esophageal Varices in Cirrhosis
- Blood Protein Signature Diagnoses Pediatric IBD and Distinguishes Subtypes
- Blood Test Detects More High-Risk Prostate Cancers Than PSA
- Rapid Blood Test Aids Diagnosis of Acute Ischemic Stroke
Channels
Clinical Chemistry
view channel
Blood Protein Panel Predicts Timing of ALS Symptom Onset
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease in which clinical signs often emerge only after substantial motor neuron injury has already occurred, complicating timely intervention.... Read more
Siemens Adds CE-Marked Capillary Claims for 24 Assays on Atellica Analyzers
Venous blood draws can be challenging in patients with difficult veins, needle phobia, or limited blood volume, and they can slow collection in busy services. Core laboratories also face pressure to expand... Read more
Molecular Diagnostics
view channel
Genomic Fingerprints Reveal Early Chemotherapy Resistance in Childhood Cancer
Chemotherapy remains central to treating childhood cancers, yet its toxic effects can injure healthy tissues, and some tumors later relapse or spread. Clinicians have lacked early molecular markers that... Read more
Blood Gene Expression Fluctuates More Than Expected Over Time
Blood-based gene expression is widely used to explore disease biology, but temporal variability can complicate interpretation of single time-point measurements. Seasonal shifts, time of day, and subclinical... Read more
Genomic Test Helps Early Breast Cancer Patients Avoid Chemotherapy
Adjuvant chemotherapy decisions in early breast cancer can expose many patients to toxicities without clear benefit when clinical factors alone do not precisely predict recurrence risk. Clinicians therefore... Read more
Residual Disease Test Predicts Merkel Cell Carcinoma Recurrence Earlier Than Antibody Assay
Merkel cell carcinoma is a rare, aggressive skin cancer with a substantial risk of relapse, occurring in about 40% of patients. Surveillance remains challenging because widely used serologic monitoring... Read moreHematology
view channel
Spectral Flow Cytometry Assay Enhances MRD Detection in Multiple Myeloma
imal residual disease (MRD) monitoring is pivotal in multiple myeloma, where persistent malignant plasma cells drive relapse risk and help guide therapy decisions. In the United States, approximately 202,000... Read more
New Marker Helps Detect Aggressive Multiple Myeloma Earlier
Multiple myeloma is an incurable malignancy of plasma cells and the second most common blood cancer worldwide, with more than 188,000 new cases each year. Although therapies have advanced, most patients... Read more
Immunology
view channel
Study Reveals Immune Mechanism Driving Severe COVID-19 Progression
Severe COVID-19 has highlighted gaps in understanding of early antiviral responses, particularly why some patients deteriorate despite timely care. Type I interferons are central to host defense, yet their... Read more
Antibody Profiling Identifies Preclinical Inflammatory Bowel Disease Years Before Diagnosis
Inflammatory bowel disease often develops after a prolonged symptom-free period, complicating timely recognition and clinical intervention. Limited understanding of immune activity during this silent phase... Read more
Ultrasensitive Blood Test Detects Sjögren’s Signature Years Before Diagnosis
Sjögren’s disease is a common autoimmune condition that can be difficult to recognize early, leading to delayed diagnosis and persistent symptom burden. It affects around half a million people in the UK... Read more
New Assays Expand Cytokine Testing for Transplant and Immunocompromised Patients
Eurofins Viracor has introduced three plasma-based assays—CXCL9 (Test Code 33607), CXCL10 (Test Code 33609), and interleukin-18 (IL-18) (Test Code 33611)—expanding its immunology testing menu for transplant... Read moreMicrobiology
view channel
High-Throughput Automated Platform to Advance Latent Tuberculosis Testing
Testing for tuberculosis remains a persistent global need, with demand driven by immigration screening, pre-treatment evaluation for immunosuppressive therapies, and public health programs.... Read more
Expanded Diagnostics and Therapies Target Rising Gonorrhea Resistance
Drug-resistant Neisseria gonorrhoeae is straining current treatment protocols and elevating the risk of complications across sexual health services. More than 500,000 cases are reported each year in the... Read more
Technology
view channel
Training Device Improves Accuracy of Pooled Molecular Diagnostics
High-throughput molecular diagnostics have transformed infectious disease detection, but many workflows remain difficult to execute accurately without extensive training. Sample pooling can cut per‑test... Read more
New CE-Certified Software Advances Whole-Genome Cancer Testing
European hospitals are increasingly using comprehensive tumor genomics to guide therapy, but routine whole genome sequencing (WGS) requires validated, regulation-compliant workflows. A newly CE-certified... Read more
National Rare Disease Registry Standardizes Genetic and Clinical Data for Coordinated Care
Rare diseases collectively impose a significant clinical burden despite their individual rarity, often involving multisystem presentations and prolonged diagnostic journeys. Limited specialist expertise... Read more
Industry
view channel
Collaboration Advances Sputum-Based Diagnostics for Asthma and COPD
Asthma and chronic obstructive pulmonary disease are highly prevalent inflammatory airway conditions, affecting more than 40 million Americans and more than 650 million people worldwide.... Read more
